Category Archives: MS Treatment

TUESDAY, Oct. 1 (HealthDay News) -- An international team of scientists has identified 48 new genetic variants associated with multiple sclerosis (MS), a new study says. The findings bring to 110 the number of genetic variants linked to MS and offer new insight into the biology of the progressive neurological disease. The genes pinpointed in the new study underline the central role played by the immune system in the development of MS and show significant overlap with genes known to be involved in other autoimmune diseases, according to the study, which was published online Sept. 29 in the journal Nature Genetics. The International Multiple Sclerosis Genetics Consortium included 193 investigators in 13 countries. They analyzed DNA from more than 29,000 people with MS and nearly 51,000 people without the disease, making it the largest MS study ever undertaken. Although there are now 110 genetic variants known to be associated with MS, each variant individually confers only a small risk of developing the disease. Collectively, these genetic variants explain about 20 percent of the genetic component of MS, the researchers said. The new findings are "a major step forward," according to study co-leader Jacob McCauley of the University of Miami Miller … Continue reading →

Novartis International AG / Real-world evidence showed superiority of Novartis' Gilenya(R) to reduce MS relapse rates compared to interferons or glatiramer acetate . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. -- Real-world data showed Gilenya reduced the annualized relapse rate and risk of relapse by around 50% versus interferons or glatiramer acetate -- Reducing the frequency and probability of future relapses in patients with MS is a key treatment goal, as relapses can significantly advance an individual's level of disability -- Recovering from a relapse can take weeks or months for a patient with MS, and approximately half of all relapses may leave lasting effects The digital press release with multimedia content can be accessed here: http://multimediacapsule.thomsonone.com/novartis/gilenya-real-world-efficacy-global-press-release Basel, October 3, 2013 - Novartis announced today findings from an international multiple sclerosis (MS) registry and a US health claims data base which showed the real-world superiority of Gilenya(R) (fingolimod) in reducing risks of relapses compared to standard therapies[1]-[3]. These data confirm the positive results seen in clinical trials with Gilenya, and were presented at the ongoing 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) … Continue reading →

Real-world data showed Gilenya reduced the annualized relapse rate and risk of relapse by around 50% versus interferons or glatiramer acetate Reducing the frequency and probability of future relapses in patients with MS is a key treatment goal, as relapses can significantly advance an individual`s level of disability Recovering from a relapse can take weeks or months for a patient with MS, and approximately half of all relapses may leave lasting effects The digital press release with multimedia content can be accessed here: Basel, October 3, 2013 - Novartis announced today findings from an international multiple sclerosis (MS) registry and a US health claims data base which showed the real-world superiority of Gilenya (fingolimod) in reducing risks of relapses compared to standard therapies[1]-[3]. These data confirm the positive results seen in clinical trials with Gilenya, and were presented at the ongoing 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark. Relapses can make life unpredictable for patients with MS and they can potentially significantly advance an individual`s level of disability[4]. MS patients` clinical outcomes are regularly assessed and switching between disease-modifying therapies (DMTs), to reduce the rate or likelihood of a relapse, … Continue reading →

WESTON, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) today announced results from several new analyses of TYSABRI (natalizumab) data that demonstrate its effectiveness in reducing multiple sclerosis (MS) disease activity. This effect was particularly significant in people with relapsing MS who initiated treatment when they had lower Expanded Disability Status Scale (EDSS) scores as well as in those who have been treated for more than two years. These data will be presented at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark from 2-5 October. These analyses build upon a growing body of evidence that demonstrates greater clinical benefits for people with MS when TYSABRI is initiated earlier in the course of the disease, as well as when TYSABRI is used for a longer duration in appropriate patients, said Alfred Sandrock, M.D., Ph.D., group senior vice president, Development Sciences and Chief Medical Officer, Biogen Idec. More Patients Demonstrated No Evidence of Clinical or MRI Disease Activity with Earlier TYSABRI Use AFFIRM was a two-year, randomized, multi-center, placebo-controlled, double-blind study of 942 patients evaluating the effect of TYSABRI on the rate of clinical relapses and the progression of disability as measured by at least … Continue reading →

TEL AVIV (Reuters) - Israel's Teva Pharmaceutical Industries and Sweden's Active Biotech said a Phase III clinical trial of laquinimod, an oral treatment for multiple sclerosis, demonstrated a beneficial impact on brain tissue damage. The study found that, compared with a placebo, patients treated with laquinimod had decreased rates in brain tissue damage shown by various MRI markers, specifically decreased rates of white matter, grey matter and thalamic atrophy, the companies said on Tuesday. The patients also developed fewer permanent black holes and accumulated less damage in normal appearing brain tissue. "These analyses reinforce our faith in the potential of laquinimod," said Michael Hayden, president of global research and development and chief scientific officer for Teva. He announced plans to initiate a clinical trial of the drug in primary progressive multiple sclerosis. "We also believe the potential neuroprotective benefits of laquinimod could have significant application in the treatment of other diseases like Crohn's disease, lupus nephritis, Huntington's disease and Alzheimer's," Hayden said. (Reporting by Tova Cohen) See more here: MS treatment reduces brain tissue damage, Teva and Active Biotech say … Continue reading →

LONDON, Oct. 2, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced that data from new MS spasticity studies (clinical trial data, observational study data and registries data collection) is being presented today at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark. The following press release was issued today by GW's commercial partner, Almirall S.A., regarding the data presentation: Copenhagen, Denmark, 2nd October 2013: Almirall S.A. (ALM) today announces the latest evidence with Sativex (THC:CBD spray) from new MS spasticity studies (clinical trial data, observational study data and registries data collection). These data, presented today at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark, show that Sativex effectiveness is maintained long term with no additional safety concerns identified in clinical practice. Two-thirds of the more than 2,000 patients with MS surveyed in the recent Spanish "6E" study reported a certain degree of spasticity, being moderate or severe in 40% of them.i "Sativex can improve the spasticity symptoms impairment of MS patients without affecting such issues as driving ability, cognition or mood," says Dr. Tiina Rekand, of the … Continue reading →

Zamboni Ms Treatment by NoMoreVitamins com REAL Holistic Health! https://theHealthFoodGuru.com. By: steve matthews … Continue reading →

London (PRWEB) September 30, 2013 An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse future trends. The past year has seen landmark changes in multiple sclerosis, with the launch of two new novel oral productsTecfidera (dimethyl fumarate; Biogen Idec) and Aubagio (teriflunomide; Sanofi) joining the first oral MS therapy, Novartiss Gilenya (fingolimod). The arrival of these drugs is expected to revolutionise multiple sclerosis treatment and be a catalyst for unprecedented market growth. Driven by in-depth interviews with the worlds leading multiple sclerosis KOLs, Therapy Trends: Multiple Sclerosis uncovers how the current treatment landscape will be impacted by significant future events, with particular focus on pipeline therapies and how these will modify the way MS is managed by neurologists in the future. Drive your strategic decision-making with inside intelligence Multiple Sclerosis: KOL Insight disseminates critical opinion and analysis to provide premier research. We cut to the heart of market-changing events and eliminate superfluous background information so you can focus on developments of greatest strategic impact and reduce your reaction time Our unique thought-leader selection matrix identifies the most influential KOLs in MS … Continue reading →

A major milestone has been reached on the path to finding a cure for multiple sclerosis (MS), researchers believe. A group of international scientists, including an Australian contingent, has discovered 48 previously unknown genes that influence the risk of developing MS. MS, which attacks a person's central nervous system and can impact mobility, balance and sensation, affects 23,000 Australians. The new discovery is a big step towards finding a cure and further treatment for the debilitating condition, says University of Sydney Associate Professor David Booth, who led the Australian and New Zealand component of the study 'The exciting thing about this is we have doubled the number of genes that we now know are associated with MS,' he told AAP. 'What that means is every one of those new genes is potentially providing us with a new way to understand the disease and to come up with new therapies for the disease.' Researchers believe the findings underline the central role the immune system plays in the development of MS. The results also show an overlap with genes found to be linked to other autoimmune diseases, including inflammatory bowel disease and celiac disease. The team of scientists, working under the umbrella … Continue reading →

A major milestone has been reached on the path to finding a cure for multiple sclerosis (MS), researchers believe. A group of international scientists, including an Australian contingent, has discovered 48 previously unknown genes that influence the risk of developing MS. MS, which attacks a person's central nervous system and can impact mobility, balance and sensation, affects 23,000 Australians. The new discovery is a big step towards finding a cure and further treatment for the debilitating condition, says University of Sydney Associate Professor David Booth, who led the Australian and New Zealand component of the study "The exciting thing about this is we have doubled the number of genes that we now know are associated with MS," he told AAP. "What that means is every one of those new genes is potentially providing us with a new way to understand the disease and to come up with new therapies for the disease." Researchers believe the findings underline the central role the immune system plays in the development of MS. The results also show an overlap with genes found to be linked to other autoimmune diseases, including inflammatory bowel disease and coeliac disease. The team of scientists, working under the umbrella … Continue reading →